Acadia Pharmaceutica
(NQ:
ACAD
)
17.59
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 13, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Acadia Pharmaceutica
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Acadia Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operating Overview
November 06, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals Enters Into an Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million
November 05, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 6, 2024
October 17, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals Announces Health Canada Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome
October 16, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Expert Outlook: ACADIA Pharmaceuticals Through The Eyes Of 5 Analysts
August 07, 2024
Via
Benzinga
A Closer Look at 13 Analyst Recommendations For ACADIA Pharmaceuticals
July 12, 2024
Via
Benzinga
Critical Insights From ACADIA Pharmaceuticals Analyst Ratings: What You Need To Know
October 10, 2024
Via
Benzinga
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 08, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 26, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
What's Going On With ACADIA Pharmaceuticals Stock?
September 24, 2024
ACADIA Pharmaceuticals shares are trading lower by 4.6% during Tuesday's session. The company appointed Catherine Owen Adams as CEO.
Via
Benzinga
Expert Ratings For ACADIA Pharmaceuticals
June 25, 2024
Via
Benzinga
Catherine Owen Adams Succeeds Steve Davis as CEO of Acadia Pharmaceuticals
September 23, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
August 28, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Jim Cramer Believes In Dell CEO, Doesn't Like B&G Foods
August 27, 2024
Cramer gives his take on E.l.f Beauty, Acadia Pharmaceuticals, B&G Foods, Lucid, SoFi, Dell, Johnson & Johnson, UWM and Symbotic.
Via
Benzinga
Ryan Reynolds Announces More to Parkinson’s® Campaign
August 14, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals to Participate in the Canaccord Genuity 44th Annual Growth Conference
August 07, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Biotech Stocks: Why Acadia Pharma And Others Are Feeling 'Growing Pains'
August 07, 2024
Acadia led a biotech selloff on Wednesday as Daybue sales missed expectations.
Via
Investor's Business Daily
Topics
Earnings
Exposures
Financial
Airbnb Reports Weak Earnings, Joins Cryoport, Tripadvisor, Lyft And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
August 07, 2024
Via
Benzinga
Acadia Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operating Overview
August 06, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2024
July 24, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Clinical Data from Open-Label Extension LILAC-1™ and LILAC-2™ Studies Evaluating Long-Term Safety and Efficacy of DAYBUE™ (trofinetide) in Patients with Rett Syndrome Published in Med
July 18, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
This Vertex Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
June 27, 2024
Via
Benzinga
Acadia Pharmaceuticals Presents DAYBUE™ (trofinetide) Real-World Evidence and Additional Data in Rett Syndrome at the 2024 International Rett Syndrome Foundation (IRSF) Annual Scientific Meeting
June 18, 2024
From
Acadia Pharmaceuticals, Inc.
Via
Business Wire
3 Sorry Pharma Stocks to Sell in May While You Still Can
May 29, 2024
Discover three pharma stocks to sell in May while you still can. Avoid these companies facing significant setbacks.
Via
InvestorPlace
After UnitedHealth Cyberattack, Drug Distributor Cencora Notifies Americans' Health Information Stolen In Data Breach In February
May 24, 2024
Cencora reports a cyberattack exposing sensitive medical information, including patient names, addresses, birth dates, diagnoses, and medications.
Via
Benzinga
Topics
Data Breach
Exposures
Information Security
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 17, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals Announces Launch of Magnolia's Guide to Adventuring: A Groundbreaking Documentary Series Aiming to Raise Disease Awareness and Redefine Perceptions of Rett Syndrome
May 15, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Shhh! 3 Secret Penny Stocks Flying Below Wall Street’s Radar
May 09, 2024
Under-the-radar penny stocks can be some of the most rewarding investments on the market. Here are three to consider.
Via
InvestorPlace
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
May 09, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
ACAD Stock Earnings: ACADIA Pharmaceuticals Beats EPS, Misses Revenue for Q1 2024
May 08, 2024
ACAD stock results show that ACADIA Pharmaceuticals beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Via
InvestorPlace
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.